| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | 5 | — | 3 | — | — | — | — | 2 | — |
| Sell | — | — | — | — | — | — | — | — | 2 | 1 | — | — |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 410.00 | 320.00 | 195.00 | 222.00 |
| Receivables | 254.00 | 287.00 | 255.00 | 287.00 |
| Inventory | 135.00 | 167.00 | 153.00 | 150.00 |
| Other | 467.00 | 21.00 | 16.00 | 54.00 |
| 1,266.00 | 827.00 | 652.00 | 725.00 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 204.00 | 216.00 | 250.00 | 206.00 |
| ST’ Debt | 3.00 | 18.00 | 29.00 | — |
| Other | 40.00 | 11.00 | — | — |
| 1,290.00 | 924.00 | 914.00 | 868.00 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 317.00 | 343.00 | — | — |
—
|
| ’25 | 266.00 | 302.00 | 314.00 | 357.00 |
1,239.00
|
| ’24 | 284.00 | 299.00 | 307.00 | 298.00 |
1,188.00
|
| ’23 | 253.00 | 276.00 | 271.00 | 293.00 |
1,093.00
|
| ’22 | 207.00 | 221.00 | 232.00 | 241.00 |
901.00
|
| ’21 | 180.00 | 201.00 | 187.00 | 223.00 |
791.00
|
| ’20 | 153.00 | 150.00 | 159.00 | 185.00 |
647.00
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (9.00) | 229.00 | — | — |
—
|
| ’25 | 75.00 | 158.00 | (39.00) | (221.00) |
(27.00)
|
| ’24 | (37.00) | 88.00 | 2.00 | (17.00) |
36.00
|
| ’23 | (36.00) | (19.00) | 21.00 | (266.00) |
(300.00)
|
| ’22 | (75.00) | 27.00 | 62.00 | (18.00) |
(4.00)
|
| ’21 | 89.00 | 71.00 | 26.00 | 167.00 |
353.00
|
| ’20 | (146.00) | (2.00) | 26.00 | (71.00) |
(193.00)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (29.00) | 222.00 | — | — |
—
|
| ’25 | 70.00 | 140.00 | (59.00) | (245.00) |
(94.00)
|
| ’24 | (40.00) | 84.00 | (5.00) | (34.00) |
5.00
|
| ’23 | (166.00) | (20.00) | (7.00) | (160.00) |
(353.00)
|
| ’22 | (74.00) | 25.00 | 60.00 | (19.00) |
(9.00)
|
| ’21 | 90.00 | 40.00 | 44.00 | 165.00 |
339.00
|
| ’20 | (146.00) | (2.00) | 24.00 | (73.00) |
(197.00)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.69 | 0.98 | — | — |
—
|
| ’25 | 0.38 | 0.14 | 0.33 | 0.79 |
1.64
|
| ’24 | 0.34 | (0.79) | 0.03 | 0.07 |
(0.36)
|
| ’23 | 0.31 | 0.27 | (0.98) | 0.38 |
0.01
|
| ’22 | 0.30 | 0.35 | 0.28 | (1.34) |
(0.38)
|
| ’21 | 0.50 | 0.40 | 0.15 | 0.25 |
1.35
|
| ’20 | (1.10) | 0.12 | 0.06 | (0.10) |
(1.00)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 3.13 | 14.38 | 7.33 | 7.62 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 22.00 | 26.50 | 23.22 | 38.00 | — | — | — |
High Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 953 | 1,164 | 1,051 | 838 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.95 | 0.94 | 1.13 | 1.48 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 901.00 | 1,093.00 | 1,188.00 | 1,239.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 82.35% | 84.08% | 80.56% | 80.15% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (95.00) | (149.00) | 20.00 | 239.00 | ‡‡‡‡‡ | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (10.54%) | (13.63%) | 1.68% | 19.29% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (85.00) | (129.00) | 7.00 | 210.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 21.00 | 15.00 | 28.00 | 20.00 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.48 | 7.98 | 9.00 | 9.91 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡ | (0.38) | 0.01 | (0.36) | 1.68 | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.03) | (2.19) | 0.27 | (0.22) | ‡‡‡‡ | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.04) | (0.39) | (0.23) | (0.54) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.06) | (2.58) | 0.04 | (0.75) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.37 | (1.39) | (2.55) | (0.78) | ‡‡‡‡‡ | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 139.01 | 137.00 | 132.00 | 125.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | 0.00 | 1,547.00 | 0.00 | 21.23 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.36 | 1.94 | 1.38 | 3.62 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 59.28 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.63 | 1.78 | 1.39 | 3.72 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (237.05) | (5.52) | 330.75 | (48.52) | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (4.00) | (300.00) | 36.00 | (27.00) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (5.00) | (53.00) | (31.00) | (67.00) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (9.00) | (353.00) | 5.00 | (94.00) | ‡‡‡‡‡ | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 240.00 | (24.00) | (97.00) | (262.00) | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 240.00 | 240.00 | 333.00 | 319.00 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (653.00) | (170.00) | 13.00 | 124.00 | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 51.00 | (191.00) | (337.00) | (98.00) | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.94%) | (7.31%) | 0.46% | 16.69% | ‡‡‡‡‡ | — | — |
ROA
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 629.81% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (41.73%) | 182.98% | (2.65%) | (96.33%) | ‡‡‡‡‡ | — | — |
ROE
|
Indivior Pharmaceuticals (INDV) is at a pivotal rebound in the addictive disorders arena, battling the opioid crisis with its disruptive SUBLOCADE injectable and promising OPNT003 pipeline for cocaine addiction. After weathering patent cliffs, legal settlements, and revenue dips from $1.09 billion peaks to $647 million lows, the company has stabilized at $1.188 billion in 2024—up 9% YoY—with revenue per share climbing to $9.00 and per employee hitting $1.13 million amid operational efficiencies. Profitability is flipping dramatically: from 2024 breakeven ($0.01 EPS) to explosive $1.76 EPS in 2025 and $3.15 by 2027, driven by 80%+ gross margins, positive free cash flow, and ROE surging to 85%.
The stock’s rollercoaster—plunging to $1.75 lows before recent undervaluation—now aligns with analyst targets implying 39% mean upside (up to 45%), supported by insider director buys totaling $172,000 in early 2026 and cleared litigation overhangs. Balance sheet strength is evident in net debt normalization and share buybacks reducing count to ~125 million, positioning INDV for rerating as SUBLOCADE captures share in the $5B+ U.S. OUD market growing at 8% CAGR.
This bull case hinges on peak SUBLOCADE sales topping $1B by 2028 and OPNT003’s Phase 3 data mid-2026 unlocking a $1B+ stimulant market, amid macro tailwinds like 80,000+ annual U.S. OUD deaths. While generic risks linger, improving metrics and insider conviction scream asymmetric upside for growth investors eyeing biotech recoveries.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.